Cognitive Function in Breast Cancer Survivors

  • Janette Vardy
Part of the Cancer Treatment and Research book series (CTAR, volume 151)

Cancer survivors have coined the terms “chemobrain” and “chemofog” to refer to the problems that patients experience with their memory and/or concentration during and after completing chemotherapy. A number of studies have confirmed that some breast cancer survivors suffer cognitive impairment after chemotherapy [1–8], although recent studies have found that some women’s cognitive impairment may predate the chemotherapy [9], and hormonal treatment may also impact on cognitive function [8, 10]. For most women the problem appears subtle and often improves after ceasing chemotherapy; however, for a subset of survivors, the symptoms are sustained and can impact significantly on their quality of life and ability to function in their everyday activities [7, 11, 12].


Breast Cancer Cognitive Impairment Breast Cancer Patient Cognitive Function Breast Cancer Survivor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Brezden CB, Phillips KA, Abdolell M, et al. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol. 2000;18:2695–701.PubMedGoogle Scholar
  2. 2.
    Ahles TA, Saykin AJ, Furstenberg CT, et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol. 2002;20:485–93.PubMedCrossRefGoogle Scholar
  3. 3.
    van Dam FS, Schagen SB, Muller MJ, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst. 1998;90:210–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Schagen SB, van Dam FS, Muller MJ, et al. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer. 1999;85:640–50.PubMedCrossRefGoogle Scholar
  5. 5.
    Wieneke MH, Dienst E. Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psycho-oncology. 1995;4:61–6.CrossRefGoogle Scholar
  6. 6.
    Tchen N, Juffs HG, Downie FP, et al. Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol. 2003;21:4175–83.PubMedCrossRefGoogle Scholar
  7. 7.
    Tannock IF, Ahles TA, Ganz PA, van Dam FS. Cognitive impairment associated with chemotherapy for cancer: Report of a Workshop. J Clin Oncol. 2004;22:2233–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Castellon SA, Ganz PA, Bower JE, et al. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol. 2004;26:955–69.PubMedCrossRefGoogle Scholar
  9. 9.
    Wefel JS, Lenzi R, Theriault R, et al. 'Chemobrain' in breast carcinoma?: A prologue. Cancer. 2004;101:466–75.PubMedCrossRefGoogle Scholar
  10. 10.
    Shilling V, Jenkins V, Fallowfield L, et al. The effects of hormone therapy on cognition in breast cancer. J Steroid Biochem Mol Biol. 2003;86:405–12.PubMedCrossRefGoogle Scholar
  11. 11.
    Ahles TA, Saykin A. Cognitive effects of standard-dose chemotherapy in patients with cancer. Cancer Invest. 2000;19:812–20.CrossRefGoogle Scholar
  12. 12.
    Downie FP, Mar Fan HG, Houede-Tchen N, et al. Cognitive function, fatigue, and menopausal symptoms in breast cancer patients receiving adjuvant chemotherapy: Evaluation with patient interview after formal assessment. Psychooncology. 2006;15:921–30.Google Scholar
  13. 13.
    Freeman JR, Broshek DK. Assessing cognitive dysfunction in breast cancer: What are the tools? Clin Breast Cancer. 2002; 3(Suppl 3):S91–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Carey CL, Woods SP, Rippeth JD, et al. Initial validation of a screening battery for the detection of HIV-associated cognitive impairment. Clin Neuropsychol. 2004;18:234–48.PubMedCrossRefGoogle Scholar
  15. 15.
    Butters N, Grant I, Haxby J, et al. Assessment of AIDS-related cognitive changes: Recommendations of the NIMH Workshop on Neuropsychological Assessment Approaches. J Clin Exp Neuropsychol. 1990;12:963–78.PubMedCrossRefGoogle Scholar
  16. 16.
    Cummings JL, Benson DF. Subcortical dementia. Review of an emerging concept. Arch Neurol. 1984;41:874–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Massman PJ, Delis DC, Butters N, et al. Are all subcortical dementias alike? Verbal learning and memory in Parkinson's and Huntington's disease patients. J Clin Exp Neuropsychol. 1990;12:729–44.PubMedCrossRefGoogle Scholar
  18. 18.
    Rao SM, Leo GJ, Bernardin L, et al. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology. 1991;41:685–91.PubMedGoogle Scholar
  19. 19.
    Heaton RK, Kirson D, Velin D, RA. Grant I. and the HNRC Group: The Utility of Clinical Ratings for Detecting Cognitive Change in HIV Infection, in Grant IM, A. (ed) Neuropsychology of HIV Infection. New York: Oxford University Press, 1994, pp.188–206.Google Scholar
  20. 20.
    Heaton RK, Grant I, Butters N, et al. The HNRC 500–neuropsychology of HIV infection at different disease stages. HIV Neurobehavioral Research Center. J Int Neuropsychol Soc. 1995;1:231–51PubMedCrossRefGoogle Scholar
  21. 21.
    Carey CL, Woods SP, Gonzalez R, et al. Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. J Clin Exp Neuropsychol. 2004;26:307–19.PubMedCrossRefGoogle Scholar
  22. 22.
    Martin EM, Sullivan TS, Reed RA, et al. Auditory working memory in HIV-1 infection. J Int Neuropsychol Soc. 2001;7:20–6.PubMedCrossRefGoogle Scholar
  23. 23.
    Durvasula RS, Miller EN, Myers HF, et al. Predictors of neuropsychological performance in HIV positive women. J Clin Exp Neuropsychol. 2001;23:149–63.PubMedCrossRefGoogle Scholar
  24. 24.
    Wechsler D. Manual for the Wechsler Adult Intelligence Scale. 3rd ed. New York: The Psychological Corporation; 1997Google Scholar
  25. 25.
    Ferguson RJ, Ahles TA. Low neuropsychologic performance among adult cancer survivors treated with chemotherapy. Curr Neurol Neurosci Rep. 2003;3:215–22.PubMedCrossRefGoogle Scholar
  26. 26.
    Minisini A, Atalay G, Bottomley A, et al. What is the effect of systemic anticancer treatment on cognitive function? Lancet Oncol. 2004;5:273–82.PubMedCrossRefGoogle Scholar
  27. 27.
    Weiss HD, Walker MD, Wiernik PH. Neurotoxicity of commonly used antineoplastic agents (second of two parts). N Engl J Med. 1974;291:127–33PubMedCrossRefGoogle Scholar
  28. 28.
    Weiss HD, Walker MD, Wiernik PH. Neurotoxicity of commonly used antineoplastic agents (first of two parts). N Engl J Med. 1974;291:75–81.PubMedCrossRefGoogle Scholar
  29. 29.
    Oxman TE, Silberfarb PM. Serial cognitive testing in cancer patients receiving chemotherapy. Am J Psychiatry. 1980;137:1263–5.PubMedGoogle Scholar
  30. 30.
    Silberfarb PM, Philibert D, Levine PM. Psychosocial aspects of neoplastic disease: II. Affective and cognitive effects of chemotherapy in cancer patients. Am J Psychiatry. 1980;137:597–601.PubMedGoogle Scholar
  31. 31.
    Kaasa S, Olsnes BT, Thorud E, et al. Reduced short-term neuropsychological performance in patients with nonsmall-cell lung cancer treated with cisplatin and etoposide. Antibiot Chemother. 1988;41:226–31.PubMedGoogle Scholar
  32. 32.
    Meyers CA, Abbruzzese JL. Cognitive functioning in cancer patients: Effect of previous treatment. Neurology. 1992;42:434–6.PubMedGoogle Scholar
  33. 33.
    Meyers CA, Byrne KS, Komaki R. Cognitive deficits in patients with small cell lung cancer before and after chemotherapy. Lung Cancer. 1995;12:231–5.PubMedCrossRefGoogle Scholar
  34. 34.
    Silberfarb PM. Chemotherapy and cognitive defects in cancer patients. Annu Rev Med. 1983;34:35–46.PubMedCrossRefGoogle Scholar
  35. 35.
    Komaki R, Meyers CA, Shin DM, et al. Evaluation of cognitive function in patients with limited small cell lung cancer prior to and shortly following prophylactic cranial irradiation. Int J Radiat Oncol Biol Phys. 1995;33:179–82.PubMedCrossRefGoogle Scholar
  36. 36.
    Phillips KA, Bernhard J. Adjuvant breast cancer treatment and cognitive function: Current knowledge and research directions. J Natl Cancer Inst. 2003;95:190–7.PubMedCrossRefGoogle Scholar
  37. 37.
    Bender CM, Sereika SM, Berga SL, et al. Cognitive impairment associated with adjuvant therapy in breast cancer. Psychooncology. 2006;15:422–30.Google Scholar
  38. 38.
    Donovan KA, Small BJ, Andrykowski MA, et al. Cognitive functioning after adjuvant chemotherapy and/or radiotherapy for early-stage breast carcinoma. Cancer. 2005;104:2499–507.PubMedCrossRefGoogle Scholar
  39. 39.
    Jenkins V, Shilling V, Deutsch G, et al. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer. 2006.Google Scholar
  40. 40.
    Mar Fan H, Houédé-Tchen N, Yi Q-L, Chemerynsky I, Downie FP, Sabate K, Tannock I.F. Fatigue, menopausal symptoms and cognitive function in women following adjuvant chemotherapy for breast cancer: One and two year follow-up of a prospective controlled study. J Clin Oncol. 2005;23:8025–32.CrossRefGoogle Scholar
  41. 41.
    O'Shaughnessy JA, Vukelja SJ, Holmes FA, et al. Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy. Clin Breast Cancer. 2005;5:439–46.PubMedCrossRefGoogle Scholar
  42. 42.
    Schagen SB, Muller MJ, Boogerd W, et al. Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients. Ann Oncol. 2002;13:1387–97.PubMedCrossRefGoogle Scholar
  43. 43.
    Scherwath A, Mehnert A, Schleimer B, et al. Neuropsychological function in high-risk breast cancer survivors after stem-cell supported high-dose therapy versus standard-dose chemotherapy: Evaluation of long-term treatment effects. Ann Oncol. 2006;17:415–23.PubMedCrossRefGoogle Scholar
  44. 44.
    Wefel JS, Lenzi R, Theriault RL, et al. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer. 2004;100:2292–9.PubMedCrossRefGoogle Scholar
  45. 45.
    Ganz PA. Cognitive dysfunction following adjuvant treatment of breast cancer: A new dose-limiting toxic effect? J Natl Cancer Inst. 1998;90:182–3.PubMedCrossRefGoogle Scholar
  46. 46.
    Ahles TA, Saykin AJ. Breast cancer chemotherapy-related cognitive dysfunction. Clin Breast Cancer. 2002;3(Suppl 3):S84–90.PubMedCrossRefGoogle Scholar
  47. 47.
    Bender CM, Paraska KK, Sereika SM, et al. Cognitive function and reproductive hormones in adjuvant therapy for breast cancer: A critical review. J Pain Symptom Manage. 2001;21:407–24.PubMedCrossRefGoogle Scholar
  48. 48.
    Cimprich B. Symptom management: Loss of concentration. Semin Oncol Nurs. 1995;11:279–88.PubMedCrossRefGoogle Scholar
  49. 49.
    McAllister TW, Ahles TA, Saykin AJ, et al. Cognitive effects of cytotoxic cancer chemotherapy: predisposing risk factors and potential treatments. Curr Psychiatry Rep. 2004;6:364–71.PubMedCrossRefGoogle Scholar
  50. 50.
    Weitzner MA, Meyers CA. Cognitive functioning and quality of life in malignant glioma patients: A review of the literature. Psychooncology. 1997;6:169–77.PubMedCrossRefGoogle Scholar
  51. 51.
    Meyers CA. Neurocognitive dysfunction in cancer patients. Oncology (Williston Park). 2000;14:75–9;discussion 79,81–2,85.PubMedGoogle Scholar
  52. 52.
    Meyers CA, Scheibel RS. Early detection and diagnosis of neurobehavioral disorders associated with cancer and its treatment. Oncology (Williston Park). 1990;4:115–22;discussion 122,126–7,130.PubMedGoogle Scholar
  53. 53.
    Meyers CA, Weitzner M, Byrne K, et al. Evaluation of the neurobehavioral functioning of patients before, during, and after bone marrow transplantation. J Clin Oncol. 1994;12:820–6.PubMedGoogle Scholar
  54. 54.
    Meyers CA, Weitzner MA. Neurobehavioral functioning and quality of life in patients treated for cancer of the central nervous system. Curr Opin Oncol. 1995;7:197–200.PubMedCrossRefGoogle Scholar
  55. 55.
    Olin JJ. Cognitive function after systemic therapy for breast cancer. Oncology (Williston Park). 2001;15:613–8;discussion 618,621–4.PubMedGoogle Scholar
  56. 56.
    O'Shaughnessy J. Chemotherapy-related cognitive dysfunction in breast cancer. Semin Oncol Nurs. 2003;19:17–24.PubMedCrossRefGoogle Scholar
  57. 57.
    O'Shaughnessy JA. Chemotherapy-induced cognitive dysfunction: A clearer picture. Clin Breast Cancer. 2003;4(Suppl 2):S89–94.PubMedCrossRefGoogle Scholar
  58. 58.
    Peterson LG, Popkin MK. Neuropsychiatric effects of chemotherapeutic agents for cancer. Psychosomatics. 1980;21:141–53.PubMedGoogle Scholar
  59. 59.
    Redd WH, Silberfarb PM, Andersen BL, et al. Physiologic and psychobehavioral research in oncology. Cancer. 1991;67:813–22.PubMedCrossRefGoogle Scholar
  60. 60.
    Rugo HS, Ahles T. The impact of adjuvant therapy for breast cancer on cognitive function: current evidence and directions for research. Semin Oncol. 2003;30:749–62.PubMedCrossRefGoogle Scholar
  61. 61.
    Saykin AJ, Ahles TA, McDonald BC. Mechanisms of chemotherapy-induced cognitive disorders: Neuropsychological, pathophysiological, and neuroimaging perspectives. Semin Clin Neuropsychiatry. 2003;8:201–16.PubMedCrossRefGoogle Scholar
  62. 62.
    Schagen SB, Muller MJ, Boogerd W, et al. Cognitive dysfunction and chemotherapy: Neuropsychological findings in perspective. Clin Breast Cancer. 2002;3(Suppl 3):S100–8.PubMedCrossRefGoogle Scholar
  63. 63.
    Oxman TE, Schnurr PP, Silberfarb PM. Assessment of cognitive function in cancer patients. Hosp J. 1986;2:99–128 .PubMedCrossRefGoogle Scholar
  64. 64.
    Silberfarb PM, Oxman TE. The effects of cancer therapies on the central nervous system. Adv Psychosom Med. 1988;18:13–25.PubMedGoogle Scholar
  65. 65.
    Tope DM, Ahles TA, Silberfarb PM. Psycho-oncology: Psychological well-being as one component of quality of life. Psychother Psychosom. 1993;60:129–47.PubMedCrossRefGoogle Scholar
  66. 66.
    Troy L, McFarland K, Littman-Power S, et al. Cisplatin-based therapy: A neurological and neuropsychological review. Psychooncology. 2000;9:29–39.PubMedCrossRefGoogle Scholar
  67. 67.
    Morse R, Rodgers J, Verrill M, et al. Neuropsychological functioning following systemic treatment in women treated for breast cancer: A review. Eur J Cancer. 2003;39:2288–97.PubMedCrossRefGoogle Scholar
  68. 68.
    Barton D, Loprinzi C. Novel approaches to preventing chemotherapy-induced cognitive dysfunction in breast cancer: the art of the possible. Clin Breast Cancer. 2002;3(Suppl 3):S121–7.PubMedCrossRefGoogle Scholar
  69. 69.
    Matsuda T, Takayama T, Tashiro M, et al. Mild cognitive impairment after adjuvant chemotherapy in breast cancer patients–evaluation of appropriate research design and methodology to measure symptoms. Breast Cancer. 2005;12:279–87.PubMedCrossRefGoogle Scholar
  70. 70.
    Raffa RB, Duong PV, Finney J, et al. Is 'chemo-fog'/'chemo-brain' caused by cancer chemotherapy? J Clin Pharm Ther. 2006;31:129–38.PubMedCrossRefGoogle Scholar
  71. 71.
    Kayl AE, Wefel JS, Meyers CA. Chemotherapy and cognition: effects, potential mechanisms, and management. Am J Ther. 2006;13:362–9.PubMedCrossRefGoogle Scholar
  72. 72.
    Castellon SA, Silverman DH, Ganz PA. Breast cancer treatment and cognitive functioning: current status and future challenges in assessment. Breast Cancer Res Treat. 2005;92:199–206.PubMedCrossRefGoogle Scholar
  73. 73.
    Wefel JS, Kayl AE, Meyers CA. Neuropsychological dysfunction associated with cancer and cancer therapies: A conceptual review of an emerging target. Br J Cancer. 2004;90:1691–6.PubMedGoogle Scholar
  74. 74.
    Baumgartner K. Neurocognitive changes in cancer patients. Semin Oncol Nurs. 2004;20:284–90.PubMedCrossRefGoogle Scholar
  75. 75.
    Paraska K, Bender CM. Cognitive dysfunction following adjuvant chemotherapy for breast cancer: Two case studies. Oncol Nurs Forum. 2003;30:473–8.PubMedCrossRefGoogle Scholar
  76. 76.
    Ahles TA. Do systemic cancer treatments affect cognitive function? Lancet Oncol. 2004;5:270–1.PubMedCrossRefGoogle Scholar
  77. 77.
    Anderson-Hanley C, Sherman ML, Riggs R, et al. Neuropsychological effects of treatments for adults with cancer: A meta-analysis and review of the literature. J Int Neuropsychol Soc. 2003;9:967–82.PubMedCrossRefGoogle Scholar
  78. 78.
    Falleti MG, Sanfilippo A, Maruff P, et al. The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: A meta-analysis of the current literature. Brain Cogn. 2005;59:60–70.PubMedCrossRefGoogle Scholar
  79. 79.
    Jansen CE, Miaskowski C, Dodd M, et al. A metaanalysis of studies of the effects of cancer chemotherapy on various domains of cognitive function. Cancer. 2005;104:2222–33.PubMedCrossRefGoogle Scholar
  80. 80.
    Stewart A, Bielajew C, Collins B, et al. A meta-analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer. Clin Neuropsychol. 2006;20:76–89.PubMedCrossRefGoogle Scholar
  81. 81.
    Wieneke MH, Dienst ER. Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psycho-oncology. 1995;4:61–6.CrossRefGoogle Scholar
  82. 82.
    Tchen N JH, Downie F, Yi Q, Hu H, et al. Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol. 2003;22(22):4175–83.Google Scholar
  83. 83.
    Mar Fan H, Vardy J, Xu W, Tannock IF. Does cognitive impairment after chemotherapy improve over time or does practice make perfect? In reply. J Clinl Oncol. 2006;24:5171–2.CrossRefGoogle Scholar
  84. 84.
    Cimprich B, So H, Ronis DL, et al. Pre-treatment factors related to cognitive functioning in women newly diagnosed with breast cancer. Psychooncology. 2005;14:70–8.PubMedCrossRefGoogle Scholar
  85. 85.
    Shilling V, Jenkins V, Morris R, et al. The effects of adjuvant chemotherapy on cognition in women with breast cancer–preliminary results of an observational longitudinal study. Breast. 2005;14:142–50.PubMedCrossRefGoogle Scholar
  86. 86.
    Symes E, Maruff P, Ajani A, et al. Issues associated with the identification of cognitive change following coronary artery bypass grafting. Aust N Z J Psychiatry. 2000;34:770–84.PubMedCrossRefGoogle Scholar
  87. 87.
    Ingraham L, Aiken, CB. An empirical approach to determining criteria for abnormality in test batteries with multiple measures. Neuropsychology. 1996;10:120–4.CrossRefGoogle Scholar
  88. 88.
    Bornstein R. Methodological and conceptual issues in the study of cognitive change in HIV infection, in Grant IM A. ed. Neuropsychology of HIV Infection. New York: Oxford University Press; 1994Google Scholar
  89. 89.
    Gonzalez R, Heaton RK, Moore DJ, et al. Computerized reaction time battery versus a traditional neuropsychological battery: Detecting HIV-related impairments. J Int Neuropsychol Soc. 2003;9:64–71.PubMedCrossRefGoogle Scholar
  90. 90.
    Vardy J. Cognitive impairment postchemotherapy. Review. American Journal of Oncology. 2004;3:568–70.Google Scholar
  91. 91.
    Shilling V, Jenkins V, Trapala IS. The (mis)classification of chemo-fog – methodological inconsistencies in the investigation of cognitive impairment after chemotherapy. Breast Cancer Res Treat. 2005;1–5.Google Scholar
  92. 92.
    Taylor MJ, Heaton RK. Sensitivity and specificity of WAIS-III/WMS-III demographically corrected factor scores in neuropsychological assessment. J Int Neuropsychol Soc. 2001;7:867–74.PubMedCrossRefGoogle Scholar
  93. 93.
    Fletcher RH, Fletcher SW, Wagner EH. Responsiveness, In: Satterfield T ed. Clinical epidemiology: the essentials 2nd ed. Baltimore: Williams & Wilkins; 1988, pp. 71–72.Google Scholar
  94. 94.
    Reitan RM, Wolfson, D. The Halstead-Reitan Neuropscyhological Test Battery: Theory and Clinical Interpretation 2nd ed. Tucson, Arizona: Neuropsychology Press, 1993.Google Scholar
  95. 95.
    White DA, Heaton RK, Monsch AU. Neuropsychological studies of asymptomatic human immunodeficiency virus-type-1 infected individuals. The HNRC Group. HIV Neurobehavioral Research Center. J Int Neuropsychol Soc. 1995;1:304–15.PubMedCrossRefGoogle Scholar
  96. 96.
    Miller EN, Wilkie FL. Computerized Testing to Assess Cognition in HIV-Positive Individuals, In Grant I, Martin A ed. Neuropsychology of HIV Infection. New York: Oxford University Press; 1994, pp. 161–75.Google Scholar
  97. 97.
    Meyers CA, Wefel JS. The use of the mini-mental state examination to assess cognitive functioning in cancer trials: no ifs, ands, buts, or sensitivity. J Clin Oncol. 2003;21:3557–8.PubMedCrossRefGoogle Scholar
  98. 98.
    Miller EN, Satz P, Visscher B. Computerized and conventional neuropsychological assessment of HIV-1-infected homosexual men. Neurology. 41:1608–16.Google Scholar
  99. 99.
    Cull A, Hay C, Love SB, et al. What do cancer patients mean when they complain of concentration and memory problems? Br J Cancer. 1996;74:1674–9.PubMedCrossRefGoogle Scholar
  100. 100.
    Servaes P, Verhagen CA, Bleijenberg G. Relations between fatigue, neuropsychological functioning, and physical activity after treatment for breast carcinoma: Daily self-report and objective behavior. Cancer. 2002;95:2017–26.PubMedCrossRefGoogle Scholar
  101. 101.
    Poppelreuter M, Weis J, Kulz AK, et al. Cognitive dysfunction and subjective complaints of cancer patients. A cross-sectional study in a cancer rehabilitation centre. Eur J Cancer. 2004;40:43–9.PubMedCrossRefGoogle Scholar
  102. 102.
    Sbordone RJ. Limitations of neuropsychological testing to predict the cognitive and behavioral functioning of persons with brain injury in real-world settings. NeuroRehabilitation. 2001;16:199–201.PubMedGoogle Scholar
  103. 103.
    Radziwillllowicz W, Radziwillllowicz, P. Subjective and objective assessment of memory functions in endogenous depression. Arch Psych Psychother. 2000;2:33–41.Google Scholar
  104. 104.
    Vermeulen J, Aldenkamp AP, Alpherts WC. Memory complaints in epilepsy: Correlations with cognitive performance and neuroticism. Epilepsy Res. 1993;15:157–70.PubMedCrossRefGoogle Scholar
  105. 105.
    Vercoulen JH, Swanink CM, Galama JM, et al. The persistence of fatigue in chronic fatigue syndrome and multiple sclerosis: Development of a model. J Psychosom Res. 1998;45:507–17.PubMedCrossRefGoogle Scholar
  106. 106.
    Sunderland A, Watts K, Baddeley AD, et al. Subjective memory assessment and test performance in elderly adults. J Gerontol. 1986;41:376–84.PubMedGoogle Scholar
  107. 107.
    Millikin CP, Rourke SB, Halman MH, et al. Fatigue in HIV/AIDS is associated with depression and subjective neurocognitive complaints but not neuropsychological functioning. J Clin Exp Neuropsychol. 2003;25:201–15.PubMedCrossRefGoogle Scholar
  108. 108.
    Heaton RK, Marcotte TD, Mindt MR, et al. The impact of HIV-associated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc. 2004;10:317–31.PubMedCrossRefGoogle Scholar
  109. 109.
    Shilling V, Jenkins V. Self-reported cognitive problems in women receiving adjuvant therapy for breast cancer. Eur J Oncol Nurs. 2007;11:6–15.Google Scholar
  110. 110.
    Booth-Jones M, Jacobsen PB, Ransom S, et al. Characteristics and correlates of cognitive functioning following bone marrow transplantation. Bone Marrow Transplant. 2005;36:695–702.PubMedCrossRefGoogle Scholar
  111. 111.
    Cimprich B. Pretreatment symptom distress in women newly diagnosed with breast cancer. Cancer Nurs. 1999;22:185–94;quiz 195.PubMedCrossRefGoogle Scholar
  112. 112.
    O'Shaughnessy JA. Effects of epoetin alfa on cognitive function, mood, asthenia, and quality of life in women with breast cancer undergoing adjuvant chemotherapy. Clin Breast Cancer. 2002;3(Suppl 3):S116–20.PubMedCrossRefGoogle Scholar
  113. 113.
    Newman T, Browner WS, Hulley SB. Enhancing causal inference in observational studies, Designing clinical research: An epidemiologic approach 2nd ed. Philadelphia, Pa., Lippincott: Williams & Wilkins; 2000, pp. 125–38.Google Scholar
  114. 114.
    Fletcher R, Fletcher SW, Wagner EH. Cause, in Satterfield T ed. Clinical Epidemiology 3rd ed. Baltimore: Lippincott Williams & Wilkins; 1996, pp. 228–48.Google Scholar
  115. 115.
    Winocur G, Vardy J, Binns MA, et al. The effects of the anti-cancer drugs, methotrexate and 5-fluorouracil, on cognitive function in mice. Pharmacol Biochem Behav. 2006;85:66–75.PubMedCrossRefGoogle Scholar
  116. 116.
    Lee GD, Longo DL, Wang Y, et al. Transient improvement in cognitive function and synaptic plasticity in rats following cancer chemotherapy. Clin Cancer Res. 2006;12:198–205.PubMedCrossRefGoogle Scholar
  117. 117.
    Inagaki M, Yoshikawa E, Matsuoka Y, et al. Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer. 2007;109:146–56.PubMedCrossRefGoogle Scholar
  118. 118.
    Saykin AJ, Ahles TA, Schoenfeld J.D. et al. Gray matter reduction on voxel-based morphometry in chemotherapy-treated cancer survivors. J Int Neuropsych Soc. 2003;9:246.Google Scholar
  119. 119.
    Booth CM, Vardy J, Crawley A, et al. Cognitive impairment associated with chemotherapy for breast cancer: An exploratory case-control study. J Clin Oncol (Meeting Abstracts). 2006;24:8501.Google Scholar
  120. 120.
    Silverman DH, Dy CJ, Castellon SA, et al. Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5–10 years after chemotherapy. Breast Cancer Res Treat. 2007;103:303–11.Google Scholar
  121. 121.
    Schagen SB, Hamburger HL, Muller MJ, et al. Neurophysiological evaluation of late effects of adjuvant high-dose chemotherapy on cognitive function. J Neurooncol. 2001;51:159–65.PubMedCrossRefGoogle Scholar
  122. 122.
    Kreukels BP, Schagen SB, Ridderinkhof KR, et al. Effects of high-dose and conventional-dose adjuvant chemotherapy on long-term cognitive sequelae in patients with breast cancer: An electrophysiologic study. Clin Breast Cancer. 2006;7:67–78.PubMedCrossRefGoogle Scholar
  123. 123.
    Kreukels BP, Schagen SB, Ridderinkhof KR, et al. Electrophysiological correlates of information processing in breast-cancer patients treated with adjuvant chemotherapy. Breast Cancer Res Treat. 2005;94:53–61.PubMedCrossRefGoogle Scholar
  124. 124.
    Vezmar S, Becker A, Bode U, et al. Biochemical and clinical aspects of methotrexate neurotoxicity. Chemotherapy. 2003;49:92–104.PubMedCrossRefGoogle Scholar
  125. 125.
    Vardy J, Wong K, Yi QL, et al. Assessing cognitive function in cancer patients. Support Care Cancer. 2006;14:1111–8.Google Scholar
  126. 126.
    Mock V, Atkinson A, Barsevick A, et al. NCCN Practice Guidelines for Cancer-Related Fatigue. Oncology (Huntington). 2000;14:151–61.PubMedGoogle Scholar
  127. 127.
    Cella D, Davis K, Breitbart W, et al. Cancer-related fatigue: Prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. J Clin Oncol. 2001;19:3385–91.PubMedGoogle Scholar
  128. 128.
    Yellen SB, Cella DF, Webster K, et al. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage. 1997;13:63–74.PubMedCrossRefGoogle Scholar
  129. 129.
    Stone P, Richards M, Hardy J. Fatigue in patients with cancer. Eur J Cancer. 1998;34:1670–6.PubMedCrossRefGoogle Scholar
  130. 130.
    Knobf MT. Physical and psychologic distress associated with adjuvant chemotherapy in women with breast cancer. J Clin Oncol. 1986;4:678–84.PubMedGoogle Scholar
  131. 131.
    Stone P, Richardson A, Ream E, et al. Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer Fatigue Forum. Ann Oncol. 2000;11:971–5,PubMedCrossRefGoogle Scholar
  132. 132.
    Stone P, Ream E, Richardson A, et al. Cancer-related fatigue–a difference of opinion? Results of a multicentre survey of healthcare professionals, patients and caregivers. Eur J Cancer Care (Engl). 2003;12:20–7.CrossRefGoogle Scholar
  133. 133.
    Ashbury FD, Findlay H, Reynolds B, et al. A Canadian survey of cancer patients' experiences: are their needs being met? J Pain Symptom Manage. 1998;16:298–306.PubMedCrossRefGoogle Scholar
  134. 134.
    Stone P. The measurement, causes and effective management of cancer-related fatigue. Int J Palliat Nurs. 2002;8:120–8.PubMedGoogle Scholar
  135. 135.
    Broeckel JA, Jacobsen PB, Horton J, et al. Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer. J Clin Oncol. 1998;16:1689–96.PubMedGoogle Scholar
  136. 136.
    Bower JE, Ganz PA, Desmond KA, et al. Fatigue in breast cancer survivors: Occurrence, correlates, and impact on quality of life. J Clin Oncol. 2000;18:743–53PubMedGoogle Scholar
  137. 137.
    Jacobsen PB, Stein K. Is Fatigue a Long-term Side Effect of Breast Cancer Treatment? Cancer Control. 1999;6:256–63.PubMedGoogle Scholar
  138. 138.
    Richardson A. Fatigue in cancer patients: A review of the literature. Eur J Cancer Care (Engl). 1995;4:20–32.CrossRefGoogle Scholar
  139. 139.
    Jacobsen PB. Assessment of fatigue in cancer patients. J Natl Cancer Inst Monogr. 2004;93–7.Google Scholar
  140. 140.
    Massie M. Depression, in Holland J, Rowland ed. Handbook of Psycho-oncology. New York: Oxford University Press; 1990, pp.283–90.Google Scholar
  141. 141.
    Keating NL, Norredam M, Landrum MB, et al. Physical and mental health status of older long-term cancer survivors. J Am Geriatr Soc. 2005;53:2145–52.PubMedCrossRefGoogle Scholar
  142. 142.
    Honda K, Goodwin RD. Cancer and mental disorders in a national community sample: Findings from the national comorbidity survey. Psychother Psychosom. 2004;73:235–42.PubMedCrossRefGoogle Scholar
  143. 143.
    Hewitt M, Rowland JH. Mental health service use among adult cancer survivors: Analyses of the National Health Interview Survey. J Clin Oncol 2002;20:4581–90.PubMedCrossRefGoogle Scholar
  144. 144.
    Fallowfield L, Ratcliffe D, Jenkins V, et al. Psychiatric morbidity and its recognition by doctors in patients with cancer. Br J Cancer. 2001;84:1011–15.PubMedCrossRefGoogle Scholar
  145. 145.
    Derogatis LR, Morrow GR, Fetting J, et al. The prevalence of psychiatric disorders among cancer patients. JAMA. 1983;249:751–7.PubMedCrossRefGoogle Scholar
  146. 146.
    Deimling GT, Kahana B, Bowman KF, et al. Cancer survivorship and psychological distress in later life. Psychooncology. 2002;11:479–94.PubMedCrossRefGoogle Scholar
  147. 147.
    Eberhardt B, Dilger S, Musial F, et al. Short-term monitoring of cognitive functions before and during the first course of treatment. J Cancer Res Clin Oncol. 2006;132:234–40.PubMedCrossRefGoogle Scholar
  148. 148.
    Eberhardt B, Dilger S, Musial F, et al. Medium-term effects of chemotherapy in older cancer patients. Support Care Cancer. 2006;14:216–22.PubMedCrossRefGoogle Scholar
  149. 149.
    Tamoxifen for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998;351:1451–67.CrossRefGoogle Scholar
  150. 150.
    Eberling JL, Wu C, Tong-Turnbeaugh R, et al. Estrogen- and tamoxifen-associated effects on brain structure and function. Neuroimage. 2004;21:364–71.PubMedCrossRefGoogle Scholar
  151. 151.
    Ernst T, Chang L, Cooray D, et al. The effects of tamoxifen and estrogen on brain metabolism in elderly women. J Natl Cancer Inst. 2002;94:592–7.PubMedCrossRefGoogle Scholar
  152. 152.
    Resnick SM, Maki PM, Rapp SR, et al. Effects of combination estrogen plus progestin hormone treatment on cognition and affect. J Clin Endocrinol Metab. 2006;91:1802–10.PubMedCrossRefGoogle Scholar
  153. 153.
    Espeland MA, Rapp SR, Shumaker SA, et al. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. JAMA. 2004;291:2959–68.PubMedCrossRefGoogle Scholar
  154. 154.
    Yaffe K, Lui LY, Grady D, et al. Cognitive decline in women in relation to non-protein-bound oestradiol concentrations. Lancet. 2000;356:708–12.PubMedCrossRefGoogle Scholar
  155. 155.
    Barrett-Connor E, Goodman-Gruen D. Cognitive function and endogenous sex hormones in older women. J Am Geriatr Soc. 1999;47:1289–93.PubMedGoogle Scholar
  156. 156.
    Ciocca DR, Roig LM. Estrogen receptors in human nontarget tissues: Biological and clinical implications. Endocr Rev. 1995;16:35–62.PubMedGoogle Scholar
  157. 157.
    Rapp SR, Espeland MA, Shumaker SA, et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: The Women's Health Initiative Memory Study: A randomized controlled trial. JAMA. 2003;289:2663–72.PubMedCrossRefGoogle Scholar
  158. 158.
    Paganini-Hill A, Clark LJ. Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat. 2000;64:165–76.PubMedCrossRefGoogle Scholar
  159. 159.
    Molassiotis A, Fernadez-Ortega P, Pud D, et al. Use of complementary and alternative medicine in cancer patients: A European survey. Ann Oncol. 2005;16:655–63.PubMedCrossRefGoogle Scholar
  160. 160.
    Tuxen MK, Hansen SW. Neurotoxicity secondary to antineoplastic drugs. Cancer Treat Rev. 1994;20:191–214.PubMedCrossRefGoogle Scholar
  161. 161.
    Joseph JA, Denisova N, Fisher D, et al. Age-related neurodegeneration and oxidative stress: Putative nutritional intervention. Neurol Clin. 1998;16:747–55.PubMedCrossRefGoogle Scholar
  162. 162.
    Fillit HM, Butler RN, O'Connell AW, et al. Achieving and maintaining cognitive vitality with aging. Mayo Clin Proc. 2002;77:681–96.PubMedCrossRefGoogle Scholar
  163. 163.
    Ahles TA, Saykin AJ. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer. 2007;7:192–201.PubMedCrossRefGoogle Scholar
  164. 164.
    Dietrich J, Han R, Yang Y, et al. CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J Biol. 2006;5:22.PubMedCrossRefGoogle Scholar
  165. 165.
    Madhyastha S, Somayaji SN, Rao MS, et al. Hippocampal brain amines in methotrexate-induced learning and memory deficit. Can J Physiol Pharmacol. 2002;80:1076–84.PubMedCrossRefGoogle Scholar
  166. 166.
    Ganz PA, Greendale GA, Petersen L, et al. Breast cancer in younger women: reproductive and late health effects of treatment. J Clin Oncol. 2003;21:4184–93.PubMedCrossRefGoogle Scholar
  167. 167.
    Jacobsen PB, Garland LL, Booth-Jones M, et al. Relationship of hemoglobin levels to fatigue and cognitive functioning among cancer patients receiving chemotherapy. J Pain Symptom Manage. 2004;28:7–18.PubMedCrossRefGoogle Scholar
  168. 168.
    Mar Fan H, Yi Q-L, Park A, Braganza S, Chang J, Couture F, Tannock IF. The influence of erythropoietin on cognitive function in women following adjuvant chemotherapy for breast cancer. San Antonio Breast Cancer Symposium. San Antonio, Texas, 2004 Abstract No. 3075Google Scholar
  169. 169.
    Ramassamy C, Averill D, Beffert U, et al. Oxidative damage and protection by antioxidants in the frontal cortex of Alzheimer's disease is related to the apolipoprotein E genotype. Free Radic Biol Med. 1999;27:544–53.PubMedCrossRefGoogle Scholar
  170. 170.
    Fishel ML, Vasko MR, Kelley MR. DNA repair in neurons: So if they don't divide what's to repair? Mutat Res. 2007;614:24–36.PubMedCrossRefGoogle Scholar
  171. 171.
    Lee AY, Levine MN. Venous thromboembolism and cancer: Risks and outcomes. Circulation. 2003;107:I17–21.PubMedGoogle Scholar
  172. 172.
    Falanga A, Levine MN, Consonni R, et al. The effect of very-low-dose warfarin on markers of hypercoagulation in metastatic breast cancer: Results from a randomized trial. Thromb Haemost. 1998;79:23–7.PubMedGoogle Scholar
  173. 173.
    Kuller LH, Evans RW. Homocysteine, vitamins, and cardiovascular disease. Circulation. 1998;98:196–9.PubMedGoogle Scholar
  174. 174.
    Shea TB, Lyons-Weiler J, Rogers E. Homocysteine, folate deprivation and Alzheimer neuropathology. J Alzheimers Dis. 2002;4:261–7.PubMedGoogle Scholar
  175. 175.
    Moss RB, Mercandetti A, Vojdani A. TNF-alpha and chronic fatigue syndrome. J Clin Immunol. 1999;19:314–16.PubMedCrossRefGoogle Scholar
  176. 176.
    Mantovani G, Maccio A, Madeddu C, et al. Quantitative evaluation of oxidative stress, chronic inflammatory indices and leptin in cancer patients: Correlation with stage and performance status. Int J Cancer. 2002;98:84–91.PubMedCrossRefGoogle Scholar
  177. 177.
    Banks WA, Farr SA, Morley JE. Entry of blood-borne cytokines into the central nervous system: Effects on cognitive processes. Neuroimmunomodulation. 2003;10:319–27.CrossRefGoogle Scholar
  178. 178.
    Pusztai L, Mendoza TR, Reuben JM, et al. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine 2004;25:94–102.PubMedCrossRefGoogle Scholar
  179. 179.
    Meyers CA, Albitar M, Estey E. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer. 2005;104:788–93.PubMedCrossRefGoogle Scholar
  180. 180.
    Lee BN, Dantzer R, Langley KE, et al. A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. Neuroimmunomodulation. 2004;11:279–92.PubMedCrossRefGoogle Scholar
  181. 181.
    Cleeland CS, Bennett GJ, Dantzer R, et al. Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer. 2003;97:2919–25.PubMedCrossRefGoogle Scholar
  182. 182.
    Valentine AD, Meyers CA. Neurobehavioral effects of interferon therapy. Curr Psychiatry Rep. 2005;7:391–5.PubMedCrossRefGoogle Scholar
  183. 183.
    Scheibel RS, Valentine AD, O'Brien S, et al. Cognitive dysfunction and depression during treatment with interferon-alpha and chemotherapy. J Neuropsychiatry Clin Neurosci. 2004;16:185–91.PubMedCrossRefGoogle Scholar
  184. 184.
    Meyers CA. Mood and cognitive disorders in cancer patients receiving cytokine therapy. Adv Exp Med Biol. 1999;461:75–81.PubMedCrossRefGoogle Scholar
  185. 185.
    Collado-Hidalgo A, Bower JE, Ganz PA, et al. Inflammatory biomarkers for persistent fatigue in breast cancer survivors. Clin Cancer Res. 2006;12:2759–66.PubMedCrossRefGoogle Scholar
  186. 186.
    Vardy J, Booth C, Pond GR, Galica J, Zhang H, Dhillon H, Clarke SJ, Tannock IF. Cytokine levels in patients with colorectal cancer and breast cancer and their relationship to fatigue and cognitive function. American Society of Clinical Oncology. Chicago, 2007Google Scholar
  187. 187.
    Liberman JN, Stewart WF, Wesnes K, et al. Apolipoprotein E epsilon 4 and short-term recovery from predominantly mild brain injury. Neurology. 2002;58:1038–44.PubMedGoogle Scholar
  188. 188.
    Tardiff BE, Newman MF, Saunders AM, et al. Preliminary report of a genetic basis for cognitive decline after cardiac operations. The Neurologic Outcome Research Group of the Duke Heart Center. Ann Thorac Surg. 1997;64:715–20.PubMedCrossRefGoogle Scholar
  189. 189.
    Roses AD, Saunders AM. ApoE, Alzheimer's disease, and recovery from brain stress. Ann N Y Acad Sci. 1997; 826:200–12.PubMedCrossRefGoogle Scholar
  190. 190.
    Ahles TA, Saykin AJ, Noll WW, et al. The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psychooncology. 2003;12:612–9.PubMedCrossRefGoogle Scholar
  191. 191.
    Jamroziak K, Robak T. Pharmacogenomics of MDR1/ABCB1 gene: The influence on risk and clinical outcome of haematological malignancies. Hematology. 2004;9:91–105.PubMedCrossRefGoogle Scholar
  192. 192.
    Kreb R. Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006;234:4–33.CrossRefGoogle Scholar
  193. 193.
    Blasiak J, Arabski M, Krupa R, et al. Basal, oxidative and alkylative DNA damage, DNA repair efficacy and mutagen sensitivity in breast cancer. Mutat Res. 2004;554:139–48.PubMedCrossRefGoogle Scholar
  194. 194.
    Morley KI, Montgomery GW. The genetics of cognitive processes: Candidate genes in humans and animals. Behav Genet. 2001;31:511–31.PubMedCrossRefGoogle Scholar
  195. 195.
    Savitz J, Solms M, Ramesar R. The molecular genetics of cognition: Dopamine, COMT and BDNF. Genes Brain Behav. 2006;5:311–28.PubMedCrossRefGoogle Scholar
  196. 196.
    Schroder CP, Wisman GB, de Jong S, et al. Telomere length in breast cancer patients before and after chemotherapy with or without stem cell transplantation. Br J Cancer. 2001;84:1348–53.PubMedCrossRefGoogle Scholar
  197. 197.
    Vasa-Nicotera M, Brouilette S, Mangino M, et al. Mapping of a major locus that determines telomere length in humans. Am J Hum Genet. 2005;76:147–51.PubMedCrossRefGoogle Scholar
  198. 198.
    Thompson SJ, Leigh L, Christensen R, et al. Immediate neurocognitive effects of methylphenidate on learning-impaired survivors of childhood cancer. J Clin Oncol. 2001;19:1802–8.PubMedGoogle Scholar
  199. 199.
    Meyers CA, Weitzner MA, Valentine AD, et al. Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. J Clin Oncol. 1998;16:2522–7.PubMedGoogle Scholar
  200. 200.
    Mar Fan HG, Chemerenysky I, Xu W, Clemons M, Tannock IF. A randomised, placebo-controlled double-blind trial of the effects of d-methylphenidate therapy on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy, Canadian Breast Cancer Research Alliance Reasons for Hope 4th Scientific Conference. Montreal, 2006 Abstract M156.Google Scholar
  201. 201.
    Lower E, Fleishman S, Cooper A, et al. A phase III, randomized placebo-controlled trial of the safety and efficacy of d-MPH as new treatment of fatigue and “chemobrain” in adult cancer patients. J Clin Oncol (Meeting Abstracts). 23:8000.Google Scholar
  202. 202.
    Le Bars PL, Kieser M, Itil KZ. A 26-week analysis of a double-blind, placebo-controlled trial of the ginkgo biloba extract EGb 761 in dementia. Dement Geriatr Cogn Disord. 2000;11:230–7.PubMedCrossRefGoogle Scholar
  203. 203.
    Le Bars PL. Response patterns of EGb 761 in Alzheimer's disease: influence of neuropsychological profiles. Pharmacopsychiatry. 2003;36(Suppl 1):S50–5.PubMedGoogle Scholar
  204. 204.
    Kleijnen J, Knipschild P. Ginkgo biloba for cerebral insufficiency. Br J Clin Pharmacol. 1992;34:352–8.PubMedGoogle Scholar
  205. 205.
    Birks J, Grimley EV, Van Dongen M. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev:CD003120. 2002.Google Scholar
  206. 206.
    Wesnes KA, Ward T, McGinty A, et al. The memory enhancing effects of a Ginkgo biloba/Panax ginseng combination in healthy middle-aged volunteers. Psychopharmacology (Berl). 2000;152:353–61.CrossRefGoogle Scholar
  207. 207.
    Kennedy DO, Scholey AB, Wesnes KA. The dose-dependent cognitive effects of acute administration of Ginkgo biloba to healthy young volunteers. Psychopharmacology (Berl). 2000;151:416–23.CrossRefGoogle Scholar
  208. 208.
    Subhan Z, Hindmarch I. The psychopharmacological effects of Ginkgo biloba extract in normal healthy volunteers. Int J Clin Pharmacol Res. 1984;4:89–93PubMedGoogle Scholar
  209. 209.
    Birks J. Does donepezil improve well-being for dementia due to Alzheimer's disease? Neuroepidemiology. 2005;24:168–9.PubMedCrossRefGoogle Scholar
  210. 210.
    Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev:CD005593. 2006.Google Scholar
  211. 211.
    Christodoulou C, Melville P, Scherl WF, et al. Effects of donepezil on memory and cognition in multiple sclerosis. J Neurol Sci. 2006;245:127–36.PubMedCrossRefGoogle Scholar
  212. 212.
    Krupp LB, Christodoulou C, Melville P, et al. Donepezil improved memory in multiple sclerosis in a randomized clinical trial. Neurology. 2004;63:1579–85.PubMedGoogle Scholar
  213. 213.
    Birks J, Flicker L. Donepezil for mild cognitive impairment. Cochrane Database Syst Rev 3:CD006104. 2006.Google Scholar
  214. 214.
    Eslinger PJ. Neuropsychological Interventions: Clinical Research and Practice. New York: Guilford Press; 2002.Google Scholar
  215. 215.
    Sohlberg MM, Mateer CA. Introduction to Cognitive Rehabilitation: Theory and Practice. New York: Guilford Press; 1989.Google Scholar
  216. 216.
    Sohlberg MM, Mateer CA. Cognitive Rehabilitation: An Integrative Neuropsychological Approach. New York: Guilford Press; 2001Google Scholar
  217. 217.
    Cicerone KD, Dahlberg C, Kalmar K, et al. Evidence-based cognitive rehabilitation: Recommendations for clinical practice. Arch Phys Med Rehabil. 2000;81:1596–615.PubMedCrossRefGoogle Scholar
  218. 218.
    Carney N, Chesnut RM, Maynard H, et al. Effect of cognitive rehabilitation on outcomes for persons with traumatic brain injury: A systematic review. J Head Trauma Rehabil. 1999;14:277–307.PubMedCrossRefGoogle Scholar
  219. 219.
    Consensus conference. Rehabilitation of persons with traumatic brain injury. NIH Consensus Development Panel on Rehabilitation of Persons with Traumatic Brain Injury. JAMA. 1999;282:974–83.Google Scholar
  220. 220.
    Mateer CA, Sira CS, O'Connell ME. Putting Humpty Dumpty together again: The importance of integrating cognitive and emotional interventions. J Head Trauma Rehabil. 2005;20:62–75.PubMedCrossRefGoogle Scholar
  221. 221.
    Sohlberg MM, McLaughlin KA, Pavese A, et al. Evaluation of attention process training and brain injury education in persons with acquired brain injury. J Clin Exp Neuropsychol. 2000;22:656–76.PubMedCrossRefGoogle Scholar
  222. 222.
    Cimprich B. Age and extent of surgery affect attention in women treated for breast cancer. Res Nurs Health. 1998;21:229–38.PubMedCrossRefGoogle Scholar
  223. 223.
    Cimprich B, Ronis DL. Attention and symptom distress in women with and without breast cancer. Nurs Res. 2001;50:86–94.PubMedCrossRefGoogle Scholar
  224. 224.
    Gottschalk LA, Holcombe RF, Jackson D, et al. The effects of anticancer chemotherapeutic drugs on cognitive function and other neuropsychiatric dimensions in breast cancer patients. Methods Find Exp Clin Pharmacol. 2003;25:117–22.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Sydney Cancer Centre, Concord Repatriation General Hospital, Department of Medical OncologyThe University of Sydney, Cancer Institute NSWSydneyAustralia

Personalised recommendations